Company Description
Henry Schein, Inc. provides health care products and services to office-based dental and medical practitioners worldwide.
It operates through Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology segments.
The Global Distribution and Value-Added Services segment distributes infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, gypsum, acrylics, articulators, abrasives, PPE products, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, dental chairs, delivery units and lights, digital dental laboratories, X-ray supplies and equipment, and high-tech and digital restoration equipment, as well as provides equipment repair services, financial services on a non-recourse basis, continuing education services for practitioners, consulting, and other services.
It also markets and sells a portfolio of consumable merchandise under its own corporate brand. The Global Specialty Products segment engage in manufacturing, marketing, and sales of dental implant and biomaterial products; and endodontic, orthodontic and orthopedic products, and other health care-related products and services.
The Global Technology segment is involved in the development and distribution of practice management software, e-services, and other products which are distributed to health care providers.
The company serves dental practices, laboratories, physician practices, and ambulatory surgery centers, as well as government, institutional health care clinics, home health providers, and other alternate care clinics.
Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.
| Country | United States |
| Founded | 1932 |
| IPO Date | Nov 3, 1995 |
| Industry | Medical Distribution |
| Sector | Healthcare |
| Employees | 25,000 |
| CEO | Frederick Lowery |
Contact Details
Address: 135 Duryea Road Melville, New York 11747 United States | |
| Phone | 631 843 5500 |
| Website | henryschein.com |
Stock Details
| Ticker Symbol | HSIC |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001000228 |
| CUSIP Number | 806407102 |
| ISIN Number | US8064071025 |
| Employer ID | 11-3136595 |
| SIC Code | 5047 |
Key Executives
| Name | Position |
|---|---|
| Ronald N. South | Senior Vice President and Chief Financial Officer |
| Michael Saul Ettinger | Executive Vice President and Chief Operating Officer |
| Mark E. Mlotek | Executive Vice President and Chief Strategic Officer |
| Olga Timoshkina | Vice President of Corporate Finance and Chief Accounting Officer |
| Christopher Pendergast | Senior Vice President and Chief Technology Officer |
| Graham Stanley | Vice President of Investor Relations and Strategic Finance Project Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 8, 2026 | ARS | Filing |
| Apr 8, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 8, 2026 | DEF 14A | Other definitive proxy statements |
| Mar 27, 2026 | SCHEDULE 13G/A | Filing |
| Mar 19, 2026 | 144 | Filing |
| Mar 10, 2026 | SCHEDULE 13D/A | Filing |
| Mar 10, 2026 | 144 | Filing |
| Mar 5, 2026 | 144 | Filing |
| Mar 4, 2026 | 144 | Filing |
| Mar 2, 2026 | 144 | Filing |